Unknown

Dataset Information

0

Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner


ABSTRACT: ABSTRACT Metformin, a drug prescribed to treat type 2 diabetes, has been reported to possess antitumor activity via immunity activation. However, the influence of metformin on natural killer (NK) cells is not fully understood. Here, we investigated whether metformin exerts a potent anticancer effect by activating NK cells. The results showed that sustained exposure to metformin enhances the cytolytic activity of NK-92 cells. Moreover, this enhancement of cytotoxicity by metformin was also observed in NK cells from healthy peripheral blood and cancer patient ascites. Mechanistically, metformin induced activation of the JAK1/2/3/STAT5 and AKT/mTOR pathways in a p38 MAPK-dependent manner rather than an AMPK-dependent manner. In vivo experiments, metformin also improved cancer surveillance of NK cells in mouse models of lymphoma clearance and metastatic melanoma. Additionally, combination treatment with metformin and anti-PD-1 antibodies increased the therapy response rates of B16F10 melanoma. Moreover, metformin treatment increased NK cell and T cell infiltration in tumors. Therefore, these results provide a deeper understanding of metformin on the effector function of NK cells and will contribute to the development and applications of metformin in cancer treatment strategies.

SUBMITTER: Xia W 

PROVIDER: S-EPMC8565822 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6961722 | biostudies-literature
| S-EPMC4659573 | biostudies-literature
| S-SCDT-10_15252-EMBR_202255472 | biostudies-other
| S-EPMC7290426 | biostudies-literature
| S-EPMC7613074 | biostudies-literature
2022-12-06 | GSE201826 | GEO
2022-12-06 | GSE217608 | GEO
| S-EPMC5382695 | biostudies-literature
| S-EPMC2064280 | biostudies-literature
| S-EPMC4754716 | biostudies-literature